Skip to main content
. 2019 Mar 21;4(6):e125294. doi: 10.1172/jci.insight.125294

Figure 2. SDCSCs have high CD44v6 expression and increased tolerance to chemotherapeutic drugs.

Figure 2

(A) Images of sphere-derived cancer stem cells (SDCSCs) and their respective parental cells. (B) Gene expression of pluripotency markers Oct4 and Nanog in SDCSCs and their parental cell lines (n = 3, Mann-Whitney’s U test). (C) Expression of the stemness-suppressive miRNAs miR-34a and miR-200c in SDCSCs and their parental cell lines (n = 3, Mann-Whitney U test). (D) Cytotoxicity from various doses of 5FU (top 2 panels) and oxaliplatin (bottom 2 panels) was assessed for SDCSCs and their respective parental cells lines, HCT116 and HT29. (E) Relative gene expression of CD44 variants in SDCSCs and their parental cell lines (n = 3, Mann-Whitney U test). (F) CD44v6 protein expression in SDCSCs and their parental cell lines, HCT116 and HT29. (G) Immunofluorescence assay of CD44v6 in SDCSCs from HCT116 cells with FITC staining (left) and DAPI nuclear staining (middle); a merged image is shown on the right. *P < 0.05, **P < 0.01, ***P < 0.001.